These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 17990866)

  • 1. Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
    Bunnage ME; Blagg J; Steele J; Owen DR; Allerton C; McElroy AB; Miller D; Ringer T; Butcher K; Beaumont K; Evans K; Gray AJ; Holland SJ; Feeder N; Moore RS; Brown DG
    J Med Chem; 2007 Nov; 50(24):6095-103. PubMed ID: 17990866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa).
    Islam I; Bryant J; May K; Mohan R; Yuan S; Kent L; Morser J; Zhao L; Vergona R; White K; Adler M; Whitlow M; Buckman BO
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1349-54. PubMed ID: 17189688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor.
    Owen DR; Bull DJ; Bunnage ME; Glossop MS; Maguire RJ; Strang RS
    Bioorg Med Chem Lett; 2010 Jan; 20(1):92-6. PubMed ID: 19954973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.
    Barrow JC; Nantermet PG; Stauffer SR; Ngo PL; Steinbeiser MA; Mao SS; Carroll SS; Bailey C; Colussi D; Bosserman M; Burlein C; Cook JJ; Sitko G; Tiller PR; Miller-Stein CM; Rose M; McMasters DR; Vacca JP; Selnick HG
    J Med Chem; 2003 Dec; 46(25):5294-7. PubMed ID: 14640538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis.
    Wang YX; da Cunha V; Vincelette J; Zhao L; Nagashima M; Kawai K; Yuan S; Emayan K; Islam I; Hosoya J; Sullivan ME; Dole WP; Morser J; Buckman BO; Vergona R
    Thromb Haemost; 2007 Jan; 97(1):54-61. PubMed ID: 17200771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structures of potent selective peptide mimetics bound to carboxypeptidase B.
    Adler M; Buckman B; Bryant J; Chang Z; Chu K; Emayan K; Hrvatin P; Islam I; Morser J; Sukovich D; West C; Yuan S; Whitlow M
    Acta Crystallogr D Biol Crystallogr; 2008 Feb; 64(Pt 2):149-57. PubMed ID: 18219114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats.
    Soni H; Sharma A; Bhatt S; Jain MR; Patel PR
    Pharmacology; 2008; 82(4):304-9. PubMed ID: 18936552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
    Lee K; Park CW; Jung WH; Park HD; Lee SH; Chung KH; Park SK; Kwon OH; Kang M; Park DH; Lee SK; Kim EE; Yoon SK; Kim A
    J Med Chem; 2003 Aug; 46(17):3612-22. PubMed ID: 12904065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structures of potent thiol-based inhibitors bound to carboxypeptidase B.
    Adler M; Bryant J; Buckman B; Islam I; Larsen B; Finster S; Kent L; May K; Mohan R; Yuan S; Whitlow M
    Biochemistry; 2005 Jul; 44(26):9339-47. PubMed ID: 15982000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The TAFI system. The new role of fibrinolysis].
    Dempfle CE
    Hamostaseologie; 2007 Sep; 27(4):278-81. PubMed ID: 17938767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin.
    Colucci M; Pentimone A; Binetti BM; Cramarossa M; Piro D; Semeraro N
    Thromb Haemost; 2002 Aug; 88(2):282-7. PubMed ID: 12195701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
    Quan ML; Lam PY; Han Q; Pinto DJ; He MY; Li R; Ellis CD; Clark CG; Teleha CA; Sun JH; Alexander RS; Bai S; Luettgen JM; Knabb RM; Wong PC; Wexler RR
    J Med Chem; 2005 Mar; 48(6):1729-44. PubMed ID: 15771420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for inhibition of carboxypeptidase B by selenium-containing inhibitor: selenium coordinates to zinc in enzyme.
    Yoshimoto N; Itoh T; Inaba Y; Ishii H; Yamamoto K
    J Med Chem; 2013 Oct; 56(19):7527-35. PubMed ID: 24010887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxyphosphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B.
    Suzuki K; Muto Y; Fushihara K; Kanemoto K; Iida H; Sato E; Kikuchi C; Matsushima T; Kato E; Nomoto M; Yoshioka S; Ishii H
    J Pharmacol Exp Ther; 2004 May; 309(2):607-15. PubMed ID: 14762098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.
    Colucci M; Semeraro N
    Thromb Res; 2012 Mar; 129(3):314-9. PubMed ID: 22113149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms.
    Mishra N; Vercauteren E; Develter J; Bammens R; Declerck PJ; Gils A
    Thromb Haemost; 2011 Jul; 106(1):90-101. PubMed ID: 21544309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis.
    Mosnier LO; Bouma BN
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2445-53. PubMed ID: 16960106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation, Co-Crystallization and Structure-Based Characterization of Anabaenopeptins as Highly Potent Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa).
    Schreuder H; Liesum A; Lönze P; Stump H; Hoffmann H; Schiell M; Kurz M; Toti L; Bauer A; Kallus C; Klemke-Jahn C; Czech J; Kramer D; Enke H; Niedermeyer THJ; Morrison V; Kumar V; Brönstrup M
    Sci Rep; 2016 Sep; 6():32958. PubMed ID: 27604544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma.
    Neill EK; Stewart RJ; Schneider MM; Nesheim ME
    Anal Biochem; 2004 Jul; 330(2):332-41. PubMed ID: 15203340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.